Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Arrowhead Pharma Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Arrowhead Pharma Corp from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
02/14/2025 | Buy Now | — | B. Riley Securities | Mayank Mamtani71% | $51 → $38 | Reiterates | Buy → Buy | Get Alert |
02/12/2025 | Buy Now | — | HC Wainwright & Co. | Patrick Trucchio47% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
02/11/2025 | Buy Now | — | RBC Capital | Luca Issi41% | $42 → $42 | Reiterates | Outperform → Outperform | Get Alert |
02/11/2025 | Buy Now | — | Chardan Capital | Keay Nakae58% | $60 → $60 | Maintains | Buy | Get Alert |
01/23/2025 | Buy Now | — | HC Wainwright & Co. | Patrick Trucchio47% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
12/20/2024 | Buy Now | — | HC Wainwright & Co. | Patrick Trucchio47% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
12/12/2024 | Buy Now | — | Chardan Capital | Keay Nakae58% | $60 → $60 | Maintains | Buy | Get Alert |
12/03/2024 | Buy Now | — | HC Wainwright & Co. | Patrick Trucchio47% | $60 → $80 | Maintains | Buy | Get Alert |
11/29/2024 | Buy Now | — | Bernstein | William Pickering44% | $27 → $24 | Maintains | Market Perform | Get Alert |
11/27/2024 | Buy Now | — | Piper Sandler | Edward Tenthoff52% | $62 → $45 | Maintains | Overweight | Get Alert |
11/27/2024 | Buy Now | — | Citigroup | Shawn Egan52% | $27 → $26 | Maintains | Neutral | Get Alert |
11/27/2024 | Buy Now | — | Chardan Capital | Keay Nakae58% | $60 → $60 | Maintains | Buy | Get Alert |
11/20/2024 | Buy Now | — | HC Wainwright & Co. | Patrick Trucchio47% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
10/11/2024 | Buy Now | — | HC Wainwright & Co. | Patrick Trucchio47% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
10/08/2024 | Buy Now | — | Piper Sandler | Edward Tenthoff52% | $62 → $62 | Reiterates | Overweight → Overweight | Get Alert |
09/26/2024 | Buy Now | — | RBC Capital | Luca Issi41% | $42 → $42 | Reiterates | Outperform → Outperform | Get Alert |
09/09/2024 | Buy Now | — | Cantor Fitzgerald | Josh Schimmer54% | — | Reiterates | → Overweight | Get Alert |
09/05/2024 | Buy Now | — | HC Wainwright & Co. | Patrick Trucchio47% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
09/03/2024 | Buy Now | — | HC Wainwright & Co. | Patrick Trucchio47% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
08/12/2024 | Buy Now | — | B. Riley Securities | Mayank Mamtani71% | $55 → $55 | Reiterates | Buy → Buy | Get Alert |
07/23/2024 | Buy Now | — | HC Wainwright & Co. | Patrick Trucchio47% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
07/17/2024 | Buy Now | — | Chardan Capital | Keay Nakae58% | $60 → $60 | Maintains | Buy | Get Alert |
07/05/2024 | Buy Now | — | HC Wainwright & Co. | Patrick Trucchio47% | $90 → $60 | Maintains | Buy | Get Alert |
06/26/2024 | Buy Now | — | Chardan Capital | Keay Nakae58% | $60 → $60 | Maintains | Buy | Get Alert |
06/20/2024 | Buy Now | — | Cantor Fitzgerald | Alethia Young76% | — | Reiterates | → Overweight | Get Alert |
06/11/2024 | Buy Now | — | HC Wainwright & Co. | Patrick Trucchio47% | $90 → $90 | Reiterates | Buy → Buy | Get Alert |
06/05/2024 | Buy Now | — | Goldman Sachs | Andrea Tan41% | → $31 | Initiates | → Neutral | Get Alert |
06/03/2024 | Buy Now | — | HC Wainwright & Co. | Patrick Trucchio47% | $90 → $90 | Reiterates | Buy → Buy | Get Alert |
06/03/2024 | Buy Now | — | Chardan Capital | Keay Nakae58% | $60 → $60 | Maintains | Buy | Get Alert |
05/13/2024 | Buy Now | — | HC Wainwright & Co. | Patrick Trucchio47% | $90 → $90 | Reiterates | Buy → Buy | Get Alert |
05/13/2024 | Buy Now | — | Morgan Stanley | Michael Ulz58% | $36 → $27 | Maintains | Equal-Weight | Get Alert |
05/10/2024 | Buy Now | — | Chardan Capital | Keay Nakae58% | $60 → $60 | Maintains | Buy | Get Alert |
02/08/2024 | Buy Now | — | HC Wainwright & Co. | Patrick Trucchio47% | $90 → $90 | Reiterates | Buy → Buy | Get Alert |
02/07/2024 | Buy Now | — | RBC Capital | Luca Issi41% | $50 → $50 | Reiterates | Outperform → Outperform | Get Alert |
02/07/2024 | Buy Now | — | Morgan Stanley | Michael Ulz58% | $34 → $36 | Maintains | Equal-Weight | Get Alert |
02/07/2024 | Buy Now | — | Citigroup | Shawn Egan52% | $33 → $34 | Maintains | Neutral | Get Alert |
01/16/2024 | Buy Now | — | RBC Capital | Luca Issi41% | $50 → $50 | Reiterates | Outperform → Outperform | Get Alert |
01/02/2024 | Buy Now | — | B of A Securities | Jason Gerberry63% | $29 → $37 | Maintains | Buy | Get Alert |
12/04/2023 | Buy Now | — | B of A Securities | Jason Gerberry63% | → $29 | Initiates | → Buy | Get Alert |
11/30/2023 | Buy Now | — | Morgan Stanley | Michael Ulz58% | $40 → $37 | Maintains | Equal-Weight | Get Alert |
11/30/2023 | Buy Now | — | RBC Capital | Luca Issi41% | → $50 | Reiterates | Outperform → Outperform | Get Alert |
09/19/2023 | Buy Now | — | Citigroup | Shawn Egan52% | → $33 | Initiates | → Neutral | Get Alert |
08/09/2023 | Buy Now | — | HC Wainwright & Co. | Patrick Trucchio47% | → $90 | Reiterates | Buy → Buy | Get Alert |
08/08/2023 | Buy Now | — | Chardan Capital | Keay Nakae58% | → $60 | Reiterates | Buy → Buy | Get Alert |
08/08/2023 | Buy Now | — | Cantor Fitzgerald | Alethia Young76% | $79 → $47 | Maintains | Overweight | Get Alert |
08/08/2023 | Buy Now | — | RBC Capital | Luca Issi41% | → $60 | Reiterates | Outperform → Outperform | Get Alert |
07/21/2023 | Buy Now | — | TD Cowen | Brendan Smith36% | — | Initiates | → Outperform | Get Alert |
07/20/2023 | Buy Now | — | B. Riley Securities | Mayank Mamtani71% | → $55 | Reiterates | Buy → Buy | Get Alert |
06/30/2023 | Buy Now | — | HC Wainwright & Co. | Patrick Trucchio47% | → $90 | Reiterates | Buy → Buy | Get Alert |
06/06/2023 | Buy Now | — | HC Wainwright & Co. | Patrick Trucchio47% | → $90 | Reiterates | Buy → Buy | Get Alert |
06/02/2023 | Buy Now | — | Piper Sandler | Edward Tenthoff52% | $52 → $59 | Maintains | Overweight | Get Alert |
06/02/2023 | Buy Now | — | Chardan Capital | Keay Nakae58% | → $60 | Reiterates | Buy → Buy | Get Alert |
05/24/2023 | Buy Now | — | Chardan Capital | Keay Nakae58% | → $60 | Reiterates | Buy → Buy | Get Alert |
05/12/2023 | Buy Now | — | SVB Leerink | Mani Foroohar46% | → $40 | Downgrade | Outperform → Market Perform | Get Alert |
05/03/2023 | Buy Now | — | RBC Capital | Luca Issi41% | → $60 | Reiterates | → Outperform | Get Alert |
05/03/2023 | Buy Now | — | Goldman Sachs | Madhu Kumar72% | $65 → $73 | Maintains | Buy | Get Alert |
05/03/2023 | Buy Now | — | Morgan Stanley | Michael Ulz58% | $37 → $40 | Maintains | Equal-Weight | Get Alert |
04/26/2023 | Buy Now | — | SMBC Nikko | David Hoang42% | → $80 | Initiates | → Outperform | Get Alert |
04/12/2023 | Buy Now | — | SVB Securities | Mani Foroohar46% | $21 → $35 | Upgrade | Market Perform → Outperform | Get Alert |
03/21/2023 | Buy Now | — | Bernstein | William Pickering44% | → $27 | Initiates | → Market Perform | Get Alert |
02/10/2023 | Buy Now | — | HC Wainwright & Co. | Patrick Trucchio47% | → $90 | Reiterates | → Buy | Get Alert |
02/10/2023 | Buy Now | — | Chardan Capital | Keay Nakae58% | → $60 | Reiterates | → Buy | Get Alert |
02/08/2023 | Buy Now | — | B. Riley Securities | Mayank Mamtani71% | $59 → $55 | Maintains | Buy | Get Alert |
02/07/2023 | Buy Now | — | RBC Capital | Luca Issi41% | $83 → $77 | Maintains | Outperform | Get Alert |
02/07/2023 | Buy Now | — | Baird | Joel Beatty68% | $60 → $58 | Maintains | Outperform | Get Alert |
02/07/2023 | Buy Now | — | Piper Sandler | Edward Tenthoff52% | $55 → $52 | Maintains | Overweight | Get Alert |
12/06/2022 | Buy Now | — | HC Wainwright & Co. | Patrick Trucchio47% | $110 → $90 | Maintains | Buy | Get Alert |
11/30/2022 | Buy Now | — | B. Riley Securities | Mayank Mamtani71% | $65 → $59 | Maintains | Buy | Get Alert |
11/29/2022 | Buy Now | — | Jefferies | Maury Raycroft31% | $92 → $75 | Maintains | Buy | Get Alert |
11/29/2022 | Buy Now | — | Morgan Stanley | Andrew Galler33% | $41 → $37 | Maintains | Equal-Weight | Get Alert |
11/29/2022 | Buy Now | — | SVB Leerink | Mani Foroohar46% | $33 → $31 | Maintains | Market Perform | Get Alert |
11/10/2022 | Buy Now | — | Piper Sandler | Edward Tenthoff52% | $72 → $64 | Maintains | Overweight | Get Alert |
11/10/2022 | Buy Now | — | SVB Leerink | Mani Foroohar46% | $32 → $33 | Maintains | Market Perform | Get Alert |
09/09/2022 | Buy Now | — | Morgan Stanley | Andrew Galler33% | → $41 | Initiates | → Equal-Weight | Get Alert |
08/08/2022 | Buy Now | — | Goldman Sachs | Madhu Kumar72% | $58 → $65 | Maintains | Buy | Get Alert |
06/03/2022 | Buy Now | — | HC Wainwright & Co. | Patrick Trucchio47% | $100 → $110 | Maintains | Buy | Get Alert |
05/24/2022 | Buy Now | — | Goldman Sachs | Madhu Kumar72% | $90 → $66 | Maintains | Buy | Get Alert |
05/11/2022 | Buy Now | — | Chardan Capital | Keay Nakae58% | $94 → $80 | Maintains | Buy | Get Alert |
05/11/2022 | Buy Now | — | Piper Sandler | Edward Tenthoff52% | $89 → $72 | Maintains | Overweight | Get Alert |
05/11/2022 | Buy Now | — | Baird | Joel Beatty68% | $71 → $60 | Upgrade | Neutral → Outperform | Get Alert |
05/11/2022 | Buy Now | — | SVB Leerink | Mani Foroohar46% | $36 → $35 | Maintains | Market Perform | Get Alert |
The latest price target for Arrowhead Pharma (NASDAQ:ARWR) was reported by B. Riley Securities on February 14, 2025. The analyst firm set a price target for $38.00 expecting ARWR to rise to within 12 months (a possible 145.64% upside). 32 analyst firms have reported ratings in the last year.
The latest analyst rating for Arrowhead Pharma (NASDAQ:ARWR) was provided by B. Riley Securities, and Arrowhead Pharma reiterated their buy rating.
The last upgrade for Arrowhead Pharmaceuticals Inc happened on April 12, 2023 when SVB Securities raised their price target to $35. SVB Securities previously had a market perform for Arrowhead Pharmaceuticals Inc.
The last downgrade for Arrowhead Pharmaceuticals Inc happened on May 12, 2023 when SVB Leerink changed their price target from N/A to $40 for Arrowhead Pharmaceuticals Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Arrowhead Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Arrowhead Pharma was filed on February 14, 2025 so you should expect the next rating to be made available sometime around February 14, 2026.
While ratings are subjective and will change, the latest Arrowhead Pharma (ARWR) rating was a reiterated with a price target of $51.00 to $38.00. The current price Arrowhead Pharma (ARWR) is trading at is $15.47, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.